Zhejiang Jiaoke: the amount of newly signed orders in the first quarter was 9.488 billion yuan, and the order stock was sufficient

Chassis Supply Chain's "iPhone Moment": China's Tier 1 Shift as LeeKr Emerges

Over the past decade, China's electric vehicle (EV) industry has evolved from a niche experiment into a leading force in the global automotive landscape. In the first ten months of 2025, China exported over 2 million EVs, nearly double the year-earlier figure. From European city streets to Southeast Asian highways and Latin American urban centers, Chinese EVs have emerged as one of the most prominent symbols of a new era of “Made in China.”

Zeekr 9X (极氪9X) to Expand Overseas in Q3, Entering Middle East, Central Asia, and European Markets as First Batch

According to the Q1 2026 earnings call held today by Geely Automobile (吉利汽车 / 0175.HK), the Zeekr 9X (极氪9X) model will officially launch its overseas layout in the third quarter of this year, with plans to gradually enter the Middle East, Central Asia, and European markets starting from September.

BYD (比亚迪) in Talks to Take Over Idle European Factories, Accelerating Localized EV Manufacturing

According to reports, BYD (比亚迪) is currently in negotiations with the Stellantis (斯特兰蒂斯) Group and several other European automakers, planning to take over idle automotive plants in regions such as Italy to utilize existing European production capacity for the advancement of localized electric vehicle (EV) manufacturing.

Leapmotor (零跑汽车) T03 Sweeps Germany with €49 Monthly Lease: Achieving "Phone Bill-Level" Car Ownership Through €3 Billion Subsidy Dividends

On May 11, Leapmotor (零跑汽车) officially launched an extremely aggressive leasing scheme for the T03 in the German market, with a starting price of just €49 per month. This price is even lower than many mid-to-high-end mobile phone plans in Germany, sending shockwaves through the entry-level electric vehicle (EV) segment.

CTTQ, Ampsourcebio Ink Agreement on Cure for NASH, T2DM

There are more than 95 plus major players and more than 90 plus nonalcoholic steatohepatitis (NASH) pipeline therapies, but none of them has been approved for marketing. Who would survive the competition in the blue-ocean market for NASH?